Quince Therapeutics, Inc. (QNCX) Operating income 2018–2025
Quince Therapeutics, Inc. (QNCX) annual operating income history from SEC filings — each fiscal year as reported.
-$58.1MFY2025 · since FY2018: -$12.1M → -$58.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$58.1M | -1.4% |
| FY2024 | -$57.3M | -65.5% |
| FY2023 | -$34.6M | +33.4% |
| FY2022 | -$52.0M | +42.4% |
| FY2021 | -$90.3M | -14.5% |
| FY2020 | -$78.9M | -101.4% |
| FY2019 | -$39.2M | -223.2% |
| FY2018 | -$12.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More QNCX financial trends
QNCX RevenueQNCX Net incomeQNCX Net marginQNCX Gross profitQNCX Gross marginQNCX Operating marginQNCX Operating cash flowQNCX Free cash flowQNCX Capital expendituresQNCX Return on equityQNCX Stock buybacksQNCX Dividends paidQNCX Total assetsQNCX Total liabilitiesQNCX Shareholders’ equityQNCX overview →